#Biotechnology #FDAApproval #ClinicalTrials
www.nasdaq.com
Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal
(RTTNews) - This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes.
#ParkinsonsDisease #StemCellTherapy #ClinicalTrials
www.yahoo.com
Aspen's personalised Parkinson's cell therapy to advance to Phase III
Add Yahoo as a preferred source to see more of our stories on Google.
Aspen Neuroscience's autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and "OFF" time in Parkinson's disease patients.
#ColorectalCancer #Immunotherapy #ClinicalTrials
www.cbsnews.com
A young dad's colon cancer spread to his lungs with no warning. He says a clinical trial led to a miracle.
Kerry Breen is a news editor at CBSNews. com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital.
N
#Alzheimers #Biomarkers #ClinicalTrials
www.nih.gov
Study measuring changes in protein structure establishes new class of Alzheimer's biomarkers
NIH-funded insights into Alzheimer's biology could help with early diagnosis, future clinical trials
In a study supported by the National Institutes of Health (NIH), researchers have identified a new type of blood-based biomarker test for Alzheimer's disease that measures structural changes in proteins, providing more information on the underlying biology of the disease than standard blood tests.
#PediatricCancer #BrainTumorResearch #ClinicalTrials
www.cbsnews.com
Colorado family prepares as funding to Pediatric Brain Tumor Consortium comes to an end
In a few days federal funding will be ending for pediatric brain tumor research, and doctors and families are wrapping up clinical trials and trying to transition the lifesaving work elsewhere.
#HIV #Healthcare #ClinicalTrials
www.yahoo.com
ViiV's four-monthly HIV drug maintains viral suppression at 12 months
Add Yahoo as a preferred source to see more of our stories on Google.
ViiV Healthcare's investigational four-monthly HIV drug maintains viral suppression at 12 months in a Phase IIb trial.
#VisionRestoration #EyeHealth #ClinicalTrials
www.forbes.com
A New Era For Blindness Treatment Is Within Sight
Seeing is believing. For patients in clinical trials for eye diseases, that truism is literal.
From stem cells to bionic vision implants, there's never been a more exciting time for novel approaches to treating devastating eye conditions.
#glioblastoma #brainhealth #clinicaltrials
www.cbsnews.com
Woman shares unlikely survival journey after migraines led to glioblastoma diagnosis: "I am truly an outlier"
Kerry Breen is a news editor at CBSNews. com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital.
#glioblastoma #cancerresearch #clinicaltrials
www.cbsnews.com
Woman shares unlikely survival journey after migraines led to glioblastoma diagnosis: "I am truly an outlier"
Kerry Breen is a news editor at CBSNews. com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital.
U
#ADHD #ClinicalTrials #MentalHealth
www.usnews.com
FDA-Approved Nerve Stimulation Device For ADHD Is Ineffective, Clinical Trial Concludes
By Dennis Thompson HealthDay ReporterTUESDAY, Jan. 20, 2026 (HealthDay News) -- A U. S. Food and Drug Administration (FDA)-approved device for treating ADHD in kids simply doesn't work, a new clinical trial says.
#Biotechnology #AutoimmuneDiseases #ClinicalTrials
www.nasdaq.com
Jade Biosciences To Report Phase I Trial Of JADE101 In 1H2026
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, announced its 2026 strategic priorities on Monday, including anticipated milestones before the 44th Annual J.
#Neuroscience #Alzheimers #ClinicalTrials
www.nasdaq.com
NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study
(RTTNews) - Neumora Therapeutics, Inc. (NMRA) has entered 2026 with momentum, announcing positive Phase 1b results for its lead candidate NMRA-511 in Alzheimer's disease agitation, along with a pipeline strategy that promises multiple clinical readouts across its neuroscience programs.
